Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Autolus Therapeutics (AUTL) EBT (2017 - 2025)

Autolus Therapeutics' EBT history spans 6 years, with the latest figure at -$91.5 million for Q4 2025.

  • For Q4 2025, EBT fell 250.04% year-over-year to -$91.5 million; the TTM value through Dec 2025 reached -$285.6 million, down 30.31%, while the annual FY2025 figure was -$285.6 million, 30.31% down from the prior year.
  • EBT reached -$91.5 million in Q4 2025 per AUTL's latest filing, down from -$78.6 million in the prior quarter.
  • In the past five years, EBT ranged from a high of -$7.4 million in Q4 2022 to a low of -$91.5 million in Q4 2025.
  • Average EBT over 4 years is -$52.7 million, with a median of -$46.7 million recorded in 2023.
  • Peak YoY movement for EBT: plummeted 939.1% in 2023, then surged 66.13% in 2024.
  • A 4-year view of EBT shows it stood at -$7.4 million in 2022, then tumbled by 939.1% to -$77.2 million in 2023, then soared by 66.13% to -$26.1 million in 2024, then tumbled by 250.04% to -$91.5 million in 2025.
  • Per Business Quant, the three most recent readings for AUTL's EBT are -$91.5 million (Q4 2025), -$78.6 million (Q3 2025), and -$47.5 million (Q2 2025).